Current pharmacotherapy for the treatment of crescentic glomerulonephritis (Q36623061)

15 August 2017

1 reference

title

Current pharmacotherapy for the treatment of crescentic glomerulonephritis (English)

1 reference

15 August 2017

0 references

1 reference

Frederick W K Tam

1

1 reference

PubMed ID

17040196

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

1 reference

15 August 2017

15

1 reference

15 August 2017

11

1 reference

15 August 2017

1353-1369

1 reference

Rapidly progressive crescentic glomerulonephritis

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Pathophysiology of ANCA-associated glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Oral antihyperglycemic agents and renal disease: new agents, new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Nephrotoxicity of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Intravenous immunoglobulin and the kidney--a two-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

21 January 2018

Goodpasture's syndrome

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Clinical features and outcome of patients with both ANCA and anti-GBM antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Plasmapheresis for crescentic IgA nephropathy: a report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Acute crescentic glomerulonephritis as a complication of a Staphylococcus aureus abscess of hip joint prosthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Immunosuppressive therapy and plasmapheresis in rapidly progressive glomerulonephritis associated with bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Effects of mycophenolic acid on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Maintenance of remission with leflunomide in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Urinary Transforming Growth Factor-beta 1 as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Contributions of IL-1beta and IL-1alpha to crescentic glomerulonephritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Suppression of experimental crescentic glomerulonephritis by interleukin-10 gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Diets for patients with chronic kidney disease, still worth prescribing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

Altered cytokine production in mice lacking P2X(7) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1353

10.1517/13543784.15.11.1353

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17040196